诺诚健华2024年营收10亿:净亏4.4亿 高瓴是第一大股东

雷递
03 Apr

雷递网 雷建平 4月3日诺诚健华医药有限公司(公司代码:688428,公司简称:诺诚健华)日前发布截至2024年12月31日的年报。年报显示,诺诚健华2024年营收为10亿元,较上年同期的7.39亿元增长36.68%。截至2024年12月31日止年度,诺诚健华的核心产品宜诺凯®(奥布替尼,布鲁顿酪氨酸激酶(“BTK”)抑制剂)产生产品收益10亿元,较2023年同期的6.71亿元增长49.1%。快速...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10